title: The evolving place of vagus nerve stimulation therapy.
abstract: Approximately 40% of patients with epilepsy have seizures that do not adequately respond to medical therapy. Vagus nerve stimulation (VNS) therapy, approved 5 years ago by the Food and Drug Administration, offers a therapeutic option for patients with pharmacoresistant seizures. This supplement updates developments with VNS therapy since its approval and suggests future directions for this still-evolving treatment.
authors.affiliation: Department of Neurology, Harvard Medical School and Beth Israel Deaconess Medical Center, 330 Brookline Avenue, KS 457, Boston, MA 02215, USA.
authors.forename: Steven C
authors.initials: SC
authors.lastname: Schachter
authors.forename: James W
authors.initials: JW
authors.lastname: Wheless
mesh_terms: D004599:Electric Stimulation Therapy / Q000639:trends*; D004829:Epilepsy, Generalized / Q000628:therapy*; D006801:Humans; D014630:Vagus Nerve / Q000502:physiology*